Polynovo Share Price and Company Fundamentals



Price
$1.845
Change
-0.025 (-1.337%)
52 week
1.65 - 4.08

Last traded: Today at 5:10 AM

Polynovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing Syntrel hernia devices for hernia repair; NovoSorb Dermal Beta Cell Implant to host pancreatic islets in the skin; and NovoSorb drug elution depots. The company was formerly known as Calzada Limited and changed its name to Polynovo Limited in November 2014. Polynovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.

Key Metrics

PE ratio

-

PB ratio

53.26

Dividend yield

Beta

1.22

Market cap

$1.19B

Enterprise value

$1.19B

Company profile

Primary activitiesPolyNovo develops and commercialises innovative medical devices using its NovoSorb technology in the treatment of burns, surgical wounds and Negative Pressure Wound Therapy.
Industry / SectorMedical Devices / Healthcare
Full time employees106
Websitehttp://www.polynovo.com.au
Mailing address320 Lorimer Street Unit 2 Port Melbourne VIC 3207 Australia
Phone / Fax61 3 8681 4050 / 61 3 8681 4099
Share registryCOMPUTERSHARE INVESTOR SERVICES PTY LIMITED

Dividends

Polynovo does not pay dividends.

Company Executives

As of Oct 2021, following are the company executives and directors listed on Polynovo.

NameTitleAgeTotal Pay
Mr. Paul Brennan BSc (Nursing), MBA, RM, RNCEO, MD & Exec. Director438.63k
Mr. Jan-Marcel Gielen C.A.CFO & Company Sec.235.49k
Ms. Teena ChadhaAPAC Marketing & Distributor Mang.
Ms. Monica BenykHR Mang.
Dr. Tim MoorePrincipal Scientist
Mr. Edward GraubartSr. VP of Sales & Marketing (Americas)

Profitability and management effectiveness

Profit margin

-15.79%

Operating margin

-15.13%

Return on assets

-7.24%

Return on equity

-19.95%

Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Polynovo is 1.19B and its enterprise value is 1.19B. The enterprise value to revenue ratio of PNV is 40.91.

The PNV's stocks Beta value is 1.22 making it 22% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.

Companies similar to Polynovo (PNV)

Polynovo (ASX:PNV) Frequently Asked Questions

1. What is Polynovo's Stock Symbol?

Polynovo trades on ASX under the ticker symbol "PNV".

2. What is Polynovo's stock price today?

One share of PNV stock can currently be purchased for approximately $1.845.

3. How can I contact Polynovo?

Polynovo's mailing address is 320 Lorimer Street Unit 2 Port Melbourne VIC 3207 Australia. The company can be reached via phone at 61 3 8681 4050.

4. What is Polynovo's official website?

The official website of Polynovo is http://www.polynovo.com.au.

5. Which share registry manages Polynovo's stock?

Polynovo's stock is managed by COMPUTERSHARE INVESTOR SERVICES PTY LIMITED.